Company profile
ARS PHARMACEUTICALS, INC.
NASDAQ:SPRYBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NEFFY | approved | $26.2MQ2 2026 | 1 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05363670 | phase2 | completed | 2022-07-28 | 2024-02-02 | ARS Pharmaceuticals, Inc. | Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma |
| NCT06927999 | phase2 | recruiting | 2025-07-09 | 2027-06-01 | ARS Pharmaceuticals, Inc. | An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria |
| NCT04930900 | phase1 | completed | 2021-08-09 | 2022-03-31 | ARS Pharmaceuticals, Inc. | Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection |
| NCT05496465 | phase2 | completed | 2022-07-28 | 2024-02-29 | ARS Pharmaceuticals, Inc. | Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares |
| NCT06834165 | phase4 | recruiting | 2025-05-20 | 2027-04-01 | ARS Pharmaceuticals, Inc. | Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 214697 | 2024-08-09 | NDA | ARS PHARMACEUTICALS OPERATIONS INC | |||||
Loading… | ||||||||